NET Recovery

What NET Recovery does

NET Recovery Corp. is a privately held Delaware-incorporated medical device and healthcare services company that delivers an FDA-cleared, non-pharmacological treatment for adults experiencing opioid withdrawal. Its core product is the NET Device, a transcutaneous alternating current stimulator (tACS) that delivers mild electrical stimulation through two adhesive electrodes placed behind each ear, targeting the brain's reward pathway disrupted by dependency. The device is worn continuously for up to 7 days, with the company reporting that 98% of users experience significant symptom reduction within the first hour and most patients feeling relief within 20-45 minutes. Clinical validation is provided by multiple peer-reviewed prospective blinded randomized controlled studies published in Frontiers in Psychiatry, including a 2025 study of 103 adults demonstrating reduced post-discharge opioid and stimulant use following residential treatment.

The company operates a direct-to-patient service model from a single clinic located at 860 NW 42nd Avenue, Suite 306, Miami, Florida, with all clinical services delivered by an autonomous Advanced Practice Registered Nurse licensed in Florida and trained in the NET Device protocol. Treatment typically spans 3-4 days and includes device application, monitoring, and once/twice-daily check-ins. NET Recovery is private-pay and does not currently accept insurance or dispense controlled substances; pricing is not publicly disclosed, and payment plans may be available. Demand generation relies on the company's websites (netrecovery.net and relief.netrecovery.net), Google and Meta paid advertising, and visibility from the Amazon Prime documentary "The Final Fix."

Between June 2021 and October 2023, NET Recovery completed five SEC Regulation D exempt securities offerings with intended amounts ranging from $400,000 to $750,000 each. The company is pursuing county and local government opioid settlement funds as a non-dilutive path to expand beyond Miami, and its FDA 510(k) clearance (K233166) provides the regulatory foundation for broader geographic and clinical deployment, including into Kratom and 7-OH withdrawal indications.

Name

NET Recovery

Legal name

NET Recovery Corp.

Website

https://netrecovery.net

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

NET Recovery Corp. is a private medical device and healthcare services company offering FDA-cleared transcutaneous alternating current stimulation (tACS) neurostimulation treatment for adults experiencing opioid withdrawal, operating a direct-pay clinic in Miami, Florida.

Ownership category

akta.pro rank

Product category

Opioid Withdrawal Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Other Ambulatory Health Care Services (6219)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs) (HLAFACAG)

Keywords

• Opioid withdrawal treatment
• Neurostimulation therapy
• TACS stimulation
• Addiction recovery services
• Non-pharmaceutical withdrawal management

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Neurostimulation Treatment Services: NET Recovery provides FDA-cleared neurostimulation services for opioid withdrawal management at their Miami office. Patients pay out-of-pocket as insurance currently does not cover the treatment. Payment plans may be available. The company operates on a fee-for-service basis with typical treatment lasting 3-4 days including device application, monitoring, and check-ins.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NET Recovery provides FDA-cleared transcutaneous alternating current stimulation (tACS) neurostimulation therapy using the NET Device to manage opioid and Kratom/7-OH withdrawal symptoms at its Miami clinic. The treatment is administered by an autonomous Advanced Practice Registered Nurse licensed in Florida and involves device application, professional monitoring, and once/twice-daily check-ins over a typical 3–4 day course, with the device worn continuously up to 7 days. Services are sold on a private-pay, fee-for-service basis.

Product overview

NET Recovery offers a single unified medical device product: the FDA-cleared NET Device™. This neurostimulation device uses transcutaneous alternating current stimulation (tACS) to target the brain's reward pathway that has been disrupted by opioid dependency. The device is applied at NET Recovery's Miami office by an APRN, and patients wear it continuously for up to 7 days with once/twice-daily monitoring check-ins. The company provides treatment services primarily at their Miami, Florida location.

Differentiator

Problem solved

Functional benefit

Products and services

• NET Device™ Neurostimulation Treatment Program

Quantifiable outcome

• 98% of users experience significant withdrawal symptom reduction within the first hour of treatment
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• American Addiction Centers: American Addiction Centers is a publicly traded operator of inpatient and outpatient substance use disorder treatment facilities across the United States. It competes for the same patient population and represents the scaled, multi-site addiction treatment operator NET Recovery aspires to become.
• Behavioral Health Group: Behavioral Health Group is one of the largest outpatient opioid addiction treatment providers in the United States, operating more than 80 locations. It is comparable as an established multi-site outpatient opioid treatment operator using primarily MAT-based protocols.
• CleanSlate Centers: CleanSlate operates a national network of outpatient addiction treatment centers, primarily providing medication-assisted treatment for opioid and alcohol use disorder. It is comparable as a scaled outpatient opioid treatment operator with established clinic infrastructure NET Recovery would need to replicate.
• Braeburn: Braeburn is a specialty pharmaceutical company developing and commercializing treatments for opioid use disorder, including buprenorphine-based products. It competes with NET Recovery for the same patient population using the established MAT paradigm.
• Brainsway: Brainsway develops deep transcranial magnetic stimulation (Deep TMS) systems FDA-cleared for depression, OCD, and smoking cessation. Its smoking cessation indication directly competes with NET Recovery's stimulant-use-disorder positioning and represents the broader neurostimulation-for-addiction category.
• Indivior: Indivior is a leading specialty pharmaceutical company focused on opioid use disorder, with products including Sublocade (long-acting injectable buprenorphine) and Suboxone. It is comparable as the dominant pharmacologic standard of care that NET Recovery's non-pharmacological device must compete against for patients and prescriber mindshare.
• Neuronetics: Neuronetics is a publicly traded neurostimulation company with FDA-cleared transcranial magnetic stimulation (TMS) therapy (NeuroStar) for major depressive disorder. It is comparable to NET Recovery as an established FDA-cleared neurostimulation device business operating in clinical outpatient settings.

Direct peers

• Spark Biomedical: Spark Biomedical develops wearable transcranial direct current stimulation (tDCS) devices, including the Sparrow device for opioid withdrawal. Like NET Recovery, it targets the same patient population with a non-pharmacological neurostimulation approach to opioid withdrawal symptom management.
• Soterix Medical: Soterix Medical manufactures tDCS and tACS neurostimulation systems used in clinical research and therapeutic applications, including addiction-related indications. It competes with NET Recovery at the device-modality level for clinical neurostimulation adoption.

Emerging players

• Apollo Neuroscience: Apollo Neuroscience makes a wearable neurostimulation device marketed for stress, sleep, and focus. While currently positioned in consumer wellness rather than addiction, it represents an emerging direct-to-consumer neurostimulation peer that could potentially expand into adjacent clinical indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/NETRecovery
• LinkedInlinkedin.com/company/netrecovery

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NET Recovery